Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2023 Earnings Conference Call May 4, 2023 5:00 PM ET
Company Participants
Joshua Higa - Vice President and Head of Investor Relations
Emil Kakkis - Founder, President and Chief Executive Officer
Erik Harris - Chief Commercial Officer and Executive Vice President
Eric Crombez - Chief Medical Officer and Executive Vice President
Aaron Olsen - Senior Vice President of Corporate Strategy and Finance
Ted Huizenga - Chief Accounting Officer
Conference Call Participants
Gena Wang - Barclays
Maury Raycroft - Jefferies
Dae Gon Ha - Stifel
Joon Lee - Truist Securities
Yaron Werber - TD Cowen
Kristen Kluska - Cantor Fitzgerald
Michael Riad - Morgan Stanley
Joel Beatty - Baird
Operator
Good afternoon, and welcome to the Ultragenyx First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. At the end of the prepared remarks, you will have an opportunity to ask questions during the Q&A portion of the call. It is now my pleasure to turn the call over to Joshua Higa, Vice President and Head of Investor Relations.
Joshua Higa
Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Eric Crombez, Chief Medical Officer; Aaron Olsen, Senior Vice President of Corporate Strategy and Finance; and Ted Huizenga, Chief Accounting Officer.
I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings.
I'll now turn the call over to Emil.
Emil Kakkis
Thanks, Josh, and good afternoon, everyone. In the first part of the year, we made meaningful progress towards generating data from our key clinical programs. The Phase 2 portion of the UX143 pivotal study for osteogenesis imperfecta is fully enrolled and the team has begun analyzing the data in advance of the data release in mid-2023.
Around that same time, we begin and -- we expect to begin dosing patients in the randomized placebo-controlled Phase 3 portion of the study. Based on the KOL feedback, we believe the Phase 3 should roll swiftly and move us that much closer to a potential therapy for patients with this bone disease.